Ratings ABIONYX Pharma Börse Stuttgart

Equities

609 FR0012616852

Market Closed - Börse Stuttgart Other stock markets 14:41:53 31/05/2024 BST			5-day change	1st Jan Change
1.166 ^EUR	+2.46%		-35.29%	-35.29%

03-14	Abionyx Pharma: to benefit from a 1ME grant from Bpifrance	CF
03-11	Abionyx: reduced net loss in 2023	CF

Strengths

For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
Analysts covering this company mostly recommend stock overweighting or purchase.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
The group usually releases upbeat results with huge surprise rates.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
The company has insufficient levels of profitability.
The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
Based on current prices, the company has particularly high valuation levels.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
ABIONYX PHARMA	-35.29%	43.66M	-
VERTEX PHARMACEUTICALS INCORPORATED	+11.91%	118B	B+
REGENERON PHARMACEUTICALS, INC.	+11.60%	106B	B+
BIONTECH SE	-4.68%	24.28B	B+
ARGENX SE	-0.82%	21.96B	B
GENMAB A/S	-10.12%	18.16B	A-
WUXI APPTEC CO., LTD.	-42.12%	16.37B	A-
BEIGENE, LTD.	-17.47%	15.56B	B
NEUROCRINE BIOSCIENCES, INC.	+2.77%	13.63B	C+
SAREPTA THERAPEUTICS, INC.	+34.58%	12.27B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes